Company Encyclopedia
View More
name
ProMIS Neurosciences
PMN.US
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy.
1.935 T
PMN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease

    ProMIS Neurosciences Inc. has completed patient enrollment for its Phase 1b clinical trial of PMN310, a therapeutic antibody for Alzheimer's disease. The trial enrolled 144 patients, exceeding the initial target. It is a randomized, double-blind, placebo-controlled study to assess safety, tolerability, pharmacokinetics, biomarkers, and clinical effects of PMN310. Interim data is expected in Q2 2026, with final results in Q4 2026. No serious adverse events reported. Results pending.

    Reuters·
    US
    PMN
    -7.38%
    Reuters·
    US
    PMN
    -7.38%

    ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026

    ProMIS Neurosciences Inc. announced that interim Phase 1b trial results for PMN310 in Alzheimer's disease will be available in Q2 2026. The trial uses plasma pTau biomarkers, including pTau217, as early endpoints. The upcoming readout aims to provide early insights into PMN310's potential disease-modifying effects.

    Reuters·
    US
    PMN
    -7.38%
    Reuters·
    US
    PMN
    -7.38%

    ProMIS Neurosciences CEO to Join Fireside Chat at Evercore Healthcare Conference

    ProMIS Neurosciences CEO Neil Warma will join a fireside chat and hold investor meetings at the 8th Annual Evercore Healthcare Conference on December 2, 2025. A live webcast will be available on the company's website.

    Reuters·
    US
    PMN
    -7.38%
    Reuters·
    US
    PMN
    -7.38%

    ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split

    ProMIS Neurosciences Inc. will implement a 1-for-25 reverse stock split of its common shares on November 28, 2025, to meet Nasdaq's minimum bid price requirement. The shares will trade on a split-adjusted basis on the Nasdaq Capital Market with a new CUSIP number 74346M505. This move aims to increase the market price of the shares.

    Reuters·
    US
    PMN
    -7.38%
    Reuters·
    US
    PMN
    -7.38%

    ProMIS Neurosciences Approves Key Shareholder Proposals

    ProMIS Neurosciences held a special shareholder meeting on November 17, 2025, approving two key proposals: a potential share consolidation and the ability to adjourn the meeting to solicit additional proxies. These decisions may impact the company's stock structure and shareholder engagement. Analysts have mixed views, with a recent Buy rating and a $5.00 price target, but TipRanks' AI Analyst rates the stock as Underperform due to financial challenges.

    Tip Ranks·
    US
    PMN
    -7.38%
    Tip Ranks·
    US
    PMN
    -7.38%
    © 2025 Longbridge｜Disclaimer